Evaluating the invasiveness of liver cancer using imaging techniques
Official title: Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
Run by Chinese PLA General Hospital · NCT06559761 · Data updated 2026-11-12
This study is testing whether non-invasive imaging can help doctors understand how aggressive liver cancer is in patients who can't have surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | January 1, 2023 |
| Main results expected | June 1, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | August 19, 2024 |
| Trial ID | NCT06559761 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-80 diagnosed with hepatocellular carcinoma who are eligible for curative-intent hepatectomy.
✕Probably not a fit
Patients with major vascular invasion, extrahepatic metastasis, or those unwilling to follow-up may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on hepatocellular carcinoma (HCC) at Stage III, aiming to assess the invasiveness and proliferation ability of the tumor through non-invasive imaging methods. The study addresses the challenge of predicting patient prognosis without relying on surgical resection, which is only available to a small percentage of patients. By utilizing imaging assessments, the research seeks to provide valuable prognostic information that can assist in clinical decision-making for patients who are not candidates for surgery.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for predicting the prognosis of HCC patients, improving treatment planning and outcomes.
How similar studies have gone: While the approach of using imaging for prognosis in HCC is gaining interest, this specific methodology remains novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * According to the WHO classification, the pathological diagnosis is hepatocellular carcinoma. * The initial treatment is curative-intent hepatectomy. * There is no evidence of major vascular/hepatic portal invasion, extrahepatic/lymph node metastasis, or other malignant tumors. * Age 18-80 years old. Exclusion Criteria: · Not meeting any one of the inclusion criteria or being unwilling/unable to follow-up.
Where it's running
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Chuan Pang
- Email: pcpang117@163.com
- Phone: 18910527022
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CD19 and CD22 in vivo CAR-T therapy for relapsed/refractory B-ALL
This study tests a one-of-a-kind in vivo CAR-T treatment that targets CD19 first and then CD22 in adults with relapsed or refractory B-ALL to see if it is safe and possibly effective.
-
Romiplostim to help platelets grow after donor stem cell transplant
This phase II trial tests whether weekly romiplostim helps patients over 18 who receive a haploidentical or fully matched unrelated donor stem cell transplant to engraft platelets faster than best supportive care.
-
Exercise effect on the lumbar multifidus in back pain
This study tests whether a 12-week home rehab program can change ultrasound features of the lumbar multifidus and reduce pain in adults with chronic non-specific low back pain from multifidus injury.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
BEX101 CAR-T at the bedside for relapsed or refractory B-cell NHL
A bedside, on-site CAR-T therapy called BEX101 is being tested in adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma to see if it is safe and can help control the disease.
-
Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant
This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.